Correction: Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation

Daihao Wei; Minyu Li; Dawei Chu; Jiandang Shi

PMC · DOI:10.3389/fonc.2025.1682157·September 29, 2025

Correction: Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation

Daihao Wei, Minyu Li, Dawei Chu, Jiandang Shi

PDF

Open Access

Abstract

Linked entities

Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.

Chemicals1

solasonine

Diseases1

osteosarcoma

Figures1

Click any figure to enlarge with its caption.

Keywords

solasonineosteosarcomanetwork pharmacologytranscriptomicsexperimental validation

Peer Reviews

No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.

Videos

No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.

Taxonomy

TopicsDiet, Metabolism, and Disease · Liver Disease Diagnosis and Treatment · Genomics, phytochemicals, and oxidative stress

Full text

There was a mistake in Figure 1 as published. We modified the relevant parameters according to the opinions of the review experts and generated a new Figure 1. The corrected Figure 1 appears below.

The original version of this article has been updated.